

Antineoplastics- Medical Infused Drugs

Policy: PHARM-M017

Origination Date: 06/30/2020

Reviewed/Revised Date: 01/27/2021

Next Review Date: 01/27/2022

Current Effective Date: 02/01/2021

Disclaimer:

1. Policies are subject to change in accordance with Federal and State notice requirements.
2. Policies outline coverage determinations for all members and clients of University of Utah Health Plans. Refer to the "Policy" and "Lines of Business" section for more information.

Purpose

Antineoplastic agents may be covered for the treatment of an appropriate cancer diagnosis.

Policy/Coverage

1. **Antineoplastics may be considered medically necessary for treatment of a cancer diagnosis if the following criteria are met:**
 - A. Request must be made by an oncologist.
 - B. The requested therapy has a Food and Drug Administration (FDA) approved indication for the diagnosis AND is listed as a category 1, 2A, or 2B* option for treatment according to the National Comprehensive Cancer Network (NCCN) Guidelines.
 - C. The requested therapy is not more costly than an approved alternative therapy or sequence of therapies that is likely to produce equivalent therapeutic results as to the treatment of the member's disease.
2. **Dosage**
 - A. Dosing must be performed in accordance to the therapy's approved package insert or NCCN guidelines.
3. **Exclusions/Contraindications**
 - A. The member has any contraindications to the requested therapy.
 - B. The request is for experimental or investigational use.
 - C. Noncompliance to prior medical or pharmacological therapy may result in denial of coverage.
4. **Approval Duration**
 - A. **Initial Authorization:** up to 12 months
 - B. **Re-Authorization:** up to 12 months. Updated clinical documentation must be submitted indicating the compliance and response to therapy, including any

improvements or stabilization of the disease. Demonstrated clinical improvement in condition is required for continuation.

5. Notes

- A. * NCCN Categories of Evidence and Consensus:
 - i. Category 1: Based upon high-level evidence, there is uniform consensus that the intervention is appropriate.
 - ii. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
 - iii. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
 - iv. Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
 - v. All recommendations are category 2A unless otherwise noted.

Lines of Business

1. University of Utah Health Insurance Plans

- A. Medicare Advantage
- B. Commercial
- C. MHC

2. University of Utah Health Plans

- A. Healthy U
- B. Healthy U Integrated

References:

- 1. National Comprehensive Cancer Network (NCCN) Guidelines

Date	Review, Revisions, Approvals
05/24/2018	Policy created
05/15/2019	Policy reviewed and approved by P&T Committee
05/12/2020	Removed table that listed Antineoplastic Drug Classes
05/20/2020	Policy reviewed and approved by P&T Committee
06/30/2020	Separated out for a medical and retail policy. Policy reviewed and approved by P&T Committee. Policy effective 07.06.20202
12/10/2020	Changed: The requested therapy has a Food and Drug Administration (FDA) approved indication for the diagnosis OR is listed as a category 1, 2A, or 2B* option for treatment according to the National Comprehensive Cancer Network (NCCN) Guidelines, to: The requested therapy has a Food and Drug Administration (FDA) approved indication for the diagnosis AND is listed as a category 1, 2A, or 2B* option for treatment according to the National Comprehensive Cancer Network (NCCN) Guidelines.
01/27/2021	Policy reviewed and approved by P&T Committee.

	Updated lines of business to match UUHP Policy Committee. Policy effective 02.01.2021
--	--

Disclaimer:

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate health care providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

U of U Health Plans makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. U of U Health Plans updates its Coverage Policies regularly, and reserves the right to amend these policies and give notice in accordance with State and Federal requirements.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from U of U Health Plans.

"University of Utah Health Plans" and its accompanying logo, and its accompanying marks are protected and registered trademarks of the provider of this Service and or University of Utah Health. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association